Patent US5082833A successfully refreshed from Google Patents.
US5082833A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Reduction of cell proliferation and enhancement of nk-cell activity
Assignee: Individual
•
Filing: 1988-06-30
•
Granted: 1992-01-21
•
Expires: 2008-06-30
Abstract
Abstract A method for moderating the rate of cellular mitosis in a living mammalian tissue having a pathologically elevated rate of cellular mitosis sensitive to treatment with a solution below which comprises perfusing said tissue under mitotic growth conditions with a safe and effective amount and concentration of a composition consisting essentially of a) inositol hexaphosphate or a physiologically acceptable salt thereof; and b) a source of inositol or a physiologically acceptable salt thereof, for a period of time sufficient to moderate the elevated rate of cellular mitosis to a normal, non-pathological rate for said tissue. The method is useful in human and mammalian diseases wherein NK cell activity is altered in the laboratory, e.g. tumors, other cancers including leukemia, immunosuppressed individuals (AIDS and transplant recipients), and in viral, fungal or protozoal infections.
Inventors
- 👤 Abulkalam M. Shamsuddin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 16:33
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61P; A61P35/00; A61P37/00; A61P37/02; A61P37/04
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
78 words
A method for moderating the rate of cellular mitosis in a living mammal having a pathologically elevated rate of cellular mitosis, which comprises administering to the mammal a safe and effective amount of solution of a) inositol hexaphosphate or a physiologically acceptable salt thereof; and b) inositol or a physiologically acceptable salt thereof, in a molar ratio of a):b) from about 1:3 to 3:1 effective to moderate the elevated rate of cellular mitosis to a normal, non-pathological rate.
Claim 2
Independent Claim
78 words
A method for moderating the rate of cellular mitosis in a living mammal having a pathologically elevated rate of cellular mitosis, which comprises administering to the mammal a safe and effective amount of solution of a) inositol hexaphosphate or a physiologically acceptable salt thereof; and b) inositol or a physiologically acceptable salt thereof, in a molar ratio of a):b) from about 1:3 to 3:1 effective to moderate the elevated rate of cellular mitosis to a normal, non-pathological rate.
Claim 3
Dependent Claim
11 words
A method of claim 1, wherein the molar ratio is 1:1.
Claim 4
Dependent Claim
12 words
A method according to claim 1, wherein the composition is administered parenterally.
Claim 5
Dependent Claim
12 words
A method according to claim 1, wherein the composition is administered orally.
Claim 6
Dependent Claim
20 words
A method according to claim 1, wherein the pathological elevated rate of cellular mitosis is caused by cancer or precancer.
Claim 7
Dependent Claim
13 words
A method according to claim 5, wherein the cancer is a blood cancer.
Claim 8
Dependent Claim
13 words
A method according to claim 5, wherein the cancer is large intestinal cancer.
Claim 9
Independent Claim
83 words
A method for enhancing the rate of KN cell activity in a living mammal having a pathologically or pharmaceutically decreased rate of tumoricidal activity and reduced NK cell activity, which comprises administering to the mammal an amount of a solution of a) inositol hexaphosphate or a physiologically acceptable salt thereof; and b) inositol or a physiologically acceptable salt thereof, in a molar ratio of a):b) of about 1:3 to 3:1, effective to enhance the rate of NK-cell activity to a normal, non-pathological rate.
Claim 10
Independent Claim
83 words
A method for enhancing the rate of KN cell activity in a living mammal having a pathologically or pharmaceutically decreased rate of tumoricidal activity and reduced NK cell activity, which comprises administering to the mammal an amount of a solution of a) inositol hexaphosphate or a physiologically acceptable salt thereof; and b) inositol or a physiologically acceptable salt thereof, in a molar ratio of a):b) of about 1:3 to 3:1, effective to enhance the rate of NK-cell activity to a normal, non-pathological rate.
Claim 11
Dependent Claim
13 words
A method according to claim 8, wherein the molar ration is about 1:1.
Claim 12
Dependent Claim
12 words
A method according to claim 8, wherein the composition is administered parenterally.
Claim 13
Dependent Claim
12 words
A method according to claim 8, wherein the composition is administered orally.
Claim 14
Dependent Claim
17 words
A method according to claim 8, wherein the decreased rate of NK-cell activity is caused by immunosuppression.
Claim 15
Dependent Claim
15 words
A method according to claim 12, wherein the immunosuppression is caused by an AIDS-related infection.
Claim 16
Dependent Claim
22 words
A method according to claim 12, wherein the immunosuppression is pharmaceutically induced by chemotherapy or in preparation for receiving a tissue transplant.
Claim 17
Dependent Claim
19 words
A method according to claim 12, wherein the immunosuppression is caused by a bacterial, viral, fungal, or protozoal infection.
Claim 18
Dependent Claim
94 words
A pharmaceutical composition capable of a) moderating the rate of cellular mitosis in a living mammal having a pathologically elevated rate of cellular mitosis or b) enhancing the rate of NK cell activity in a living mammal having a pathologically or pharmaceutically decreased rate of tumoricidal activity, which comprises a safe and effective amount and concentration per unit dosage of a composition consisting essentially of a) inositol hexaphosphate or a physiologically acceptable salt thereof; and b) inositol or a physiologically acceptable salt thereof in a molar ratio of a):b) of about 1:3 to 3:1.
Claim 19
Dependent Claim
94 words
A pharmaceutical composition capable of a) moderating the rate of cellular mitosis in a living mammal having a pathologically elevated rate of cellular mitosis or b) enhancing the rate of NK cell activity in a living mammal having a pathologically or pharmaceutically decreased rate of tumoricidal activity, which comprises a safe and effective amount and concentration per unit dosage of a composition consisting essentially of a) inositol hexaphosphate or a physiologically acceptable salt thereof; and b) inositol or a physiologically acceptable salt thereof in a molar ratio of a):b) of about 1:3 to 3:1.
Claim 20
Dependent Claim
15 words
A composition according to claim 16, wherein the molar ratio of a):b) is about 1:1.
Claim 21
Dependent Claim
14 words
A composition according to claim 16, as a sterile liquid adapted for parenteral administration.
Claim 22
Dependent Claim
13 words
A composition according to claim 16, as a solid adapted for oral administration.
Claim 23
Dependent Claim
13 words
A composition according to claim 16, as a liquid adapted for oral administration.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-01-20 | 1995-07-22 | 1996-01-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-01-20 | 1999-07-22 | 2000-01-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-01-20 | 2003-07-22 | 2004-01-21 | $7700.00 | Window Closed / Lapsed |